Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Lilly

Two Drugmakers Paid More Than a Quarter Million American Prescribers as Weight Loss Drug Sales Climbed

An analysis of federal payment data found Eli Lilly and Novo Nordisk paid over 250,000 US prescribers as GLP-1 weight loss drug sales grew.

Medical Daily

Can a New Weight Loss Treatment Escape the Legal and Regulatory Thicket?

It’s Eli Lilly vs. RFK Jr. in a battle over the rules around retatrutide.

Reason

Revolution Medicines Got Its Breakthrough—What Moves It Next?

FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

A $2.88 Billion Reason Why Eli Lilly Stock Is in Focus Today

Eli Lilly announced a $2.88 billion acquisition of Merida Biosciences. Here’s what it means for LLY shares.

Barchart

Mounjaro Can Now Be Prescribed to Lower Heart Attack and Stroke Risk in Adults with Type 2 Diabetes

FDA approved Mounjaro to lower the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes at high risk.

Medical Daily

Eli Lilly diabetes drug wins FDA approval to lower cardiovascular risks

Heart disease is is the leading cause of death for people with Type 2 diabetes

The Independent UK

Eli Lilly’s Mounjaro wins FDA approval for a major new cardiovascular benefit

Eli Lilly's Mounjaro received FDA approval for reducing heart attack and stroke risks. This new indication expands its use beyond diabetes and weight management. The drug demonstrated an 8% greater reduction in cardiovascular events in a key study. Mounjaro's approval strengthens Eli Lilly's position in the GLP-1 medicine market. This…

The Economic Times

Read news from The Economist, FT, and more,
with one subscription

Eli Lilly Presses Payment Processors and Social Platforms as Federal Enforcement Struggles to Slow Retatrutide Sales

With FDA enforcement stalled at the warning-letter stage, Lilly is pressuring credit card companies and social media platforms to cut off retatrutide sellers.

Medical Daily

An Amino Acid Dispute Between Eli Lilly and the FDA Could Delay Cheaper Retatrutide by Years

A federal court fight over whether retatrutide counts as a biologic will decide if patients wait 12 years or five for cheaper competition.

Medical Daily

2 Biotech Stocks Shaping Up for Major Breakouts

Moderna's mRNA cancer vaccine breakthrough with Merck fueled a biotech rally, with the IBB near highs. Eli Lilly and Natera both show strong uptrends and possible breakouts.

MarketBeat

An Obesity Shot No Regulator Has Ever Approved Is Being Sold at Medical Spas Across the Country

Retatrutide is not approved anywhere in the world, yet clinics and med spas sell it. Poison center exposures rose 265 percent in early 2026.

Medical Daily

The Obesity Drug Race Moves Past Ozempic with a Shot Targeting Three Hormones

Eli Lilly's retatrutide produced up to 30.3% average weight loss in phase 3 trials. Approval is not expected before 2027 at the earliest.

Medical Daily

Eli Lilly’s Foundayo becomes first oral weight-loss drug approved in UK for diabetes

Britain's regulator approved Eli Lilly's Foundayo pill for weight and diabetes. This treatment is not yet available through the NHS in the UK. Foundayo will launch privately later this month via prescription. Novo Nordisk's Wegovy pill also received approval for the UK market. The weight-loss drug market is seeing increased…

The Economic Times

Vanderbilt Will Build an AI Agent into Medical Records to Cut the Wait for Alzheimer's Infusions

Vanderbilt will build an AI triage agent into its EHR to speed Alzheimer's patients to treatment. What it would do, and who is funding it.

Medical Daily

Get all your
news in one place.

100's of premium titles.
One news app.

Medical Daily

Eczema Patients on Ebglyss Can Stretch Maintenance Shots to Every Eight Weeks, but Only After a Full Induction Course

FDA approved every-eight-week Ebglyss maintenance dosing for atopic dermatitis. Who qualifies, what maintenance dosing means, and what to ask.

Medical Daily

FDA Grants Breakthrough Therapy Status to a Pancreatic Cancer Drug for a Mutation Found in Roughly 1 in 50 Patients

FDA gave olomorasib breakthrough therapy status for KRAS G12C pancreatic cancer. What the designation means, who it applies to, and what it does not prove.

Medical Daily

Retatrutide Will Not Reach the FDA Until Early 2027, Leaving No Price and No Coverage Decision to Point To

Lilly will not file retatrutide with the FDA until early 2027. What that delay means for cost, insurance coverage, and patients considering waiting.

Medical Daily

Lilly Files Its GLP-1 Pill for Diabetes, and the Manufacturing Case Is Stronger Than the Access Case

Lilly submitted its oral GLP-1 for type 2 diabetes. Why pills are easier to manufacture than injectables, and why coverage still decides access.

Get all your
news in one place.

100's of premium titles.
One news app.

Medical Daily

Lilly Says Weight Loss Drug Prices Fell 13 Percent Worldwide, but the US Decline Was Far Smaller

Lilly reported a 13% drop in realized prices, but US prices fell only 3%. Here is what that means for Zepbound patients and out-of-pocket costs.

Barchart

Eli Lilly Stock: Analyst Estimates & Ratings

Eli Lilly's market-beating performance has done little to temper Wall Street's optimism, with analysts continuing to see meaningful upside in the stock.

Medical Daily

Adding a Muscle Targeting Antibody to Semaglutide Cut Lean Mass Loss from 7.4% to 2.9% in a Phase 2 Trial

A 507-person trial found bimagrumab plus semaglutide protected lean mass while increasing fat loss. The drug remains investigational.

International Business Times

Bank of America CEO Says The Company Spends $250 Million A Year on GLP-1 Drugs for Their Employees. He Calls It a Good Investment

Bank of America CEO Brian Moynihan said the company has dramatically increased its investment in medications such as Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Zepbound.

Barchart

LLY Stock Alert: What to Know as Eli Lilly Teams Up With CVS on Weight-Loss Drugs

Eli Lilly shares rally on a fresh DTC partnership with CVS Health. A strong Q2 release and impressive future guidance is driving LLY stock higher as well.

Benzinga

Eli Lilly's Weight-Loss Empire Keeps Expanding As Mounjaro, Zepbound Generate Nearly $15 Billion

Eli Lilly and Co. (NYSE:LLY) stock traded higher Wednesday after the drugmaker reported second-quarter results that topped Wall Street expectations and raised its full-year revenue outlook, driven by continued demand for its diabetes and obesity treatments.

International Business Times

Eli Lilly Raises Sales Forecast As Weight Loss Drug Demand Soars. Its Stock is Climbing

Eli Lilly posted stronger-than-expected second-quarter earnings and revenue, boosted by surging demand for Zepbound and Mounjaro, while its newly launched obesity pill Foundayo made its first contribution to quarterly sales.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Justice Department

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.